Market Overview

Goldman Sachs Models 22% Downside To Myriad Genetics

Goldman Sachs Models 22% Downside To Myriad Genetics

Shares of the molecular diagnostics name Myriad Genetics (NYSE: MYGN) are worth less than what the Street is paying, according to Goldman Sachs. 

The Analyst

Goldman Sachs analyst Patrick Donnelly initiated coverage of Myriad Genetics with a Sell and $32 price target, implying a 22-percent downside. 

The Thesis

While acknowledging the company’s board portfolio and commercial reach, Donnelly expressed concern on the GeneSight genetic testing product cycle and said the risk-reward is “skewed to the downside."

Myriad Genetics' valuation has overstated the value of contract reimbursement revenue, the analyst said. 

Our Sell rating acknowledges MYGN’s broad portfolio and effective commercial reach as differentiating factors relative to the rest of diagnostics," Donnelly said. 

"However, we believe the market has priced in the expected stabilization of the Hereditary Cancer Testing business and valuation overstates the risk-reward from the GeneSight product cycle, where private payor reimbursement is the key lever to drive MYGN EPS growth commensurate with its 30x NTM EPS multiple."

Price Action

Myriad shares were down 6.24 percent at $38.45 at the close Monday. 

Related Link:

Increased Confidence Earns Myriad Genetics An Upgrade

Goldman Sachs: Qiagen Has 'Strategic Appeal,' M&A Potential

Latest Ratings for MYGN

Sep 2019DowngradesNeutralUnderperform
Aug 2019MaintainsHold
Aug 2019DowngradesOverweightEqual-Weight

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Goldman Sachs molecular diagnosticsAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga


Related Articles (MYGN)

View Comments and Join the Discussion!

Latest Ratings

BKNGConsumer Edge ResearchInitiates Coverage On2,250.0
EXPEConsumer Edge ResearchInitiates Coverage On100.0
TRIPConsumer Edge ResearchInitiates Coverage On26.0
IAreteInitiates Coverage On39.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

ICYMI: AMD Earnings Preview, Dell And VMware, Dr. Pepper's Deal, Wynn Resorts

8 Stocks Moving In Monday's After-Hours Session